Isis Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Published: Apr, 2015 | Pages: 78 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Isis Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Summary 

Global Markets Direct's, 'Isis Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Isis Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Isis Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Isis Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Isis Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Isis Pharmaceuticals, Inc.'s pipeline products

Reason To Buy 

- Evaluate Isis Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Isis Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Isis Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Isis Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Isis Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Isis Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Isis Pharmaceuticals, Inc. Snapshot 7
Isis Pharmaceuticals, Inc. Overview 7
Key Information 7
Key Facts 7
Isis Pharmaceuticals, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Isis Pharmaceuticals, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
Isis Pharmaceuticals, Inc. - Pipeline Products Glance 17
Isis Pharmaceuticals, Inc. - Late Stage Pipeline Products 17
Phase III Products/Combination Treatment Modalities 17
Isis Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Isis Pharmaceuticals, Inc. - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
Isis Pharmaceuticals, Inc. - Drug Profiles 22
ISIS-TTRRx 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
nusinersen 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ISIS-CRPRx 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ISIS-EIF4ERx 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ISIS-FXIRx 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ISIS-GCCRRx 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ISIS-GCGRRx 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ISIS-PTP1BRx 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ISIS-DMPK-2.5 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ISIS-APOALRx 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ISIS-FGFR4Rx 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ISIS-HBVRx 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ISIS-PKKRx 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Antisense Oligonucleotide to Inhibit C9ORF72 Protein for Amyotrophic Lateral Sclerosis 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Antisense Oligonucleotide to Inhibit Cide B for Hyperlipidemia and Atherosclerosis 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ISIS-AATRx 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ISIS-AGTLRx 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ISIS-APOCIIILRx 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ISIS-BIIB3Rx 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ISIS-DGAT2Rx 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ISIS-FVIIRx 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ISIS-GHRLRx 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ISIS-HTTRx 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ISISGSK-4L 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ISISGSK-6L 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ISISRHO-2.5Rx 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Antisense Oligonucleotide 1 for Neurological and Neuromuscular Disorders 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Antisense Oligonucleotide 2 for Neurological and Neuromuscular Disorders 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Antisense Oligonucleotides to Inhibit BCL11A and KLF1 for Hematological Disorders 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Isis Pharmaceuticals, Inc. - Pipeline Analysis 53
Isis Pharmaceuticals, Inc. - Pipeline Products by Target 53
Isis Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 55
Isis Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 56
Isis Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 57
Isis Pharmaceuticals, Inc. - Recent Pipeline Updates 59
Isis Pharmaceuticals, Inc. - Dormant Projects 71
Isis Pharmaceuticals, Inc. - Discontinued Pipeline Products 72
Discontinued Pipeline Product Profiles 72
ISIS-104838 72
ISIS-113715 72
ISIS-14803 72
ISIS-2503 72
ISIS-5132 73
ISIS-CRPRx 73
ISIS-EIF4ERx 73
Isis Pharmaceuticals, Inc. - Company Statement 74
Isis Pharmaceuticals, Inc. - Locations And Subsidiaries 76
Head Office 76
Other Locations & Subsidiaries 76
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 77
Disclaimer 78

List of Tables

Isis Pharmaceuticals, Inc., Key Information 7
Isis Pharmaceuticals, Inc., Key Facts 7
Isis Pharmaceuticals, Inc. - Pipeline by Indication, 2015 9
Isis Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 11
Isis Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 12
Isis Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2015 13
Isis Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 14
Isis Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015 15
Isis Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 16
Isis Pharmaceuticals, Inc. - Phase III, 2015 17
Isis Pharmaceuticals, Inc. - Phase II, 2015 18
Isis Pharmaceuticals, Inc. - Phase I, 2015 19
Isis Pharmaceuticals, Inc. - Preclinical, 2015 20
Isis Pharmaceuticals, Inc. - Discovery, 2015 21
Isis Pharmaceuticals, Inc. - Pipeline by Target, 2015 54
Isis Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015 55
Isis Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015 56
Isis Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015 58
Isis Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015 59
Isis Pharmaceuticals, Inc. - Dormant Developmental Projects,2015 71
Isis Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015 72
Isis Pharmaceuticals, Inc., Subsidiaries 76